Rheumatology

"I lost total mental capacity and fell apart," he said

Adverse outcomes no more common than in general population, with one exception

CAR-T therapy might hold the key

Health news and commentary gathered by MedPage Today staff

Markedly increased risk for death, CV events in long-term follow-up

Or at least safer for patients who have no better treatment options

Recent advances may get closer to a cure or prevention

Catching up with a quarter-century of research and drug launches

Registries show half of patients with active disease and pain despite ongoing therapy

Also in TTHealthWatch: the Mediterranean diet and IBS

Results move deucravacitinib to brink of approval for PsA

B cell-targeting drug could treat numerous other autoimmune diseases

Strong efficacy, safety seen in phase II data

And not even a very effective one

Standard recommendations lead to too much or too little in most patients

Studies suggest strategies that may help

Autopsy data show massive abnormalities are common

Oral IL-23 blocker highly effective in teens, phase III data confirm

"More research is needed before drawing firm conclusions," researcher says

Prescriptions mostly from non-rheumatologists, study shows

Most patients stayed flare-free, as long as they kept taking the drug

Study identifies factors tied to successful outcomes

Health news and commentary gathered by MedPage Today staff

For patients receiving CAR T-cell therapy for cancer, less toxicity and shorter hospital stay

Meta-analysis of over 200 randomized trials points to one winner for the short and medium terms

Study finds lower arthritis risk with SGLT2 inhibitors, but number needed to treat was large

Safety could be problematic, however

Fusion protein targets both BLyS and APRIL

About one in five men over age 50 will suffer an osteoporotic fracture in their remaining years

Analysis turned up 200,000 unneeded procedures that cost Medicare $2 billion over 3 years

Researchers were aiming to improve on bimekizumab for joint penetration

Drug didn't meet efficacy threshold and doubled serious adverse event risk, analysis suggests

Scandinavian study pinpoints three major risk factors, two being modifiable

Winners unraveled an additional way the body keeps the system in check